Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
MENLO PARK, Calif., April 06, 2017 -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a leading gene therapy company advancing novel medicines to address unmet needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day.
Event: Alliance for Regenerative Medicine’s Cell & Gene Therapy Investor Day
Date: April 27, 2017
Time: 5:00 pm EDT
Location: Boston, MA
A live and replay video webcast of the presentation will be available at http://www.arminvestorday.com/webcast.
About Adverum Biotechnologies, Inc.
Adverum is a gene therapy company advancing novel medicines that can offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat wet age-related macular degeneration (wAMD) and rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Contacts for Adverum: Leone Patterson Chief Financial Officer Adverum Biotechnologies, Inc. 650-665-7222 [email protected] Jill Steier Senior Vice President The Trout Group LLC 646-378-2946 [email protected]
